Dosing and Administration

Panzyga® supports the easy and convenient intravenous administration to patients with the advantage of colour-coded vials, a range of vial and pack sizes and room temperature storage. These well considered features reinforce our commitment and support to tailoring optimised solutions for healthcare professionals, patients and caregivers.

Panzyga® dose & infusion calculator

Panzyga® dose & infusion calculator (Access here)

The treatment effect should be evaluated following each treatment cycle; if no treatment effect is seen after 6 months, the treatment should be discontinued. Long-term treatment should be subject to the physician's review based upon the patient's initial response and maintenance response to treatment. The dosing and treatment intervals may need to be adapted according to the individual course of the disease.1 Please refer to information in the Summary of Product Characteristics

Panzyga® dosing recommendations1

The dose and dose regimen are dependent on the indication and may need to be individualised for each patient dependent on the clinical response.

The posology in children and adolescents (0–18 years) is not different to that of adults as the posology for each indication is given by body weight and adjusted to the clinical outcome.

Patients should be observed for at least 20 minutes after administration.1

Primary immunodeficiency syndrome (PID)

Starting dose	Maintenance dose	Frequency
0.4–0.8 g/kg	0.2–0.8 g/kg	every 3–4 weeks

Secondary  immunodeficiency (SID)

Starting dose	Frequency
0.4–0.8 g/kg	every 3–4 weeks

Primary immune  thrombocytopenia (ITP)

Starting dose	Frequency
0.8–1.0 g/kg	on day 1, possibly repeated once within 3 days or
0.4 g/kg/d	for 2–5 days

Chronic inflammatory  demyelinating polyneuropathy (CIDP)

Starting dose	Frequency	Maintenance dose	Frequency
2.0 g/kg	in divided doses over 2–5 days	1.0 g/kg	over 1–2 consecutive days every 3 weeks

Panzyga® packaging and storage1

Available in different vial and pack sizes
Provides for dosing accuracy and flexibility
Helps reduce storage space and wastage

Ease of storage

3 years shelf life at +2 °C to +8 °C
12 months shelf life at room temperature (+8 °C and below +25°C). Once removed from refrigeration, product should be discarded if not used after 12 months.

For all patients, especially the young, elderly or those with increased risk factors, IVIg administration requires:1

Panzyga® administration1

Panzyga® should be infused intravenously. When administering panzyga®, please consider the following recommendations:

Start: 0.6 ml/kg/hr for 30 min
Max: 4.8 ml/kg/hr in all patients or 8.4 ml/kg/hr in PID patients

Flush with either 0.9% saline or 5% dextrose solution to infuse all product

Do not mix with other medicinal products, nor with any other IVIg products

Bring to room or body temperature before use

Do not use solutions that are cloudy or have deposits

Switching to panzyga®

When you switch your patients to panzyga®, assess each situation individually and use caution to transition patients carefully.1

Switch after the last infusion of previous IVIg brand, commencing at the same dose and infusion frequency.1

Switching patients to panzyga®

Avoid potential complications¹

Starting the infusion rate at: 0.6 mL/kg/hr for 30 min.

Monitoring for potential adverse signs during the first infusion and for the first hour after the first infusion

In case of adverse reaction, either the rate of administration must be reduced, or the infusion stopped. The treatment required depends on the nature and severity of the adverse reaction. In case of shock, standard medical treatment for shock should be implemented. The name and the batch number of the administered product should be clearly recorded.1

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions.1

Drug safety related information should be reported to safetyreporting@octapharma.com. Please consider the pharmacovigilance data privacy statement if you are reporting drug safety relevant events.

References

Panzyga® Summary of Product Characteristics.

This is an international website for Panzyga® and is intended for healthcare professionals outside the US. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EU SmPC).
If you wish to contact Octapharma please use the contact form on our corporate website www.octapharma.com.